SCHEMBL31376118

SCHEMBL31376118

CC(C)(C)OC(=O)NCCCN1CCN(CCC=O)CC1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 11/20 0.56
SIGMAR1 Q99720 3/20 0.50
TDP1 Q9NUW8 1/20 0.48
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
GAA P10253 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CACNA1H O95180 1/20 0.46
ACHE P22303 1/20 0.43
BACE1 P56817 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30380723 0.92 DRD2 (0.54) DRD2SIGMAR1TDP1MAOAMAOB
SCHEMBL8254760 0.90 DRD2 (0.64) DRD2SIGMAR1TDP1GAAMEN1
SCHEMBL13609474 0.85 DRD2 (0.60) DRD2SIGMAR1TDP1GAAMEN1
SCHEMBL9127008 0.85 DRD2 (0.60) DRD2SIGMAR1TDP1GAAMEN1
SCHEMBL5429289 0.84 DRD2 (0.57) DRD2SIGMAR1TDP1MAOAMAOB
SCHEMBL30380945 0.84 DRD2 (0.59) DRD2SIGMAR1TDP1GAAMEN1
SCHEMBL30380052 0.84 TDP1 (0.64) DRD2SIGMAR1TDP1GAAMEN1
SCHEMBL16708685 0.84 DRD2 (0.59) DRD2SIGMAR1TDP1GAAMEN1
SCHEMBL3524057 0.84 DRD2 (0.66) DRD2SIGMAR1TDP1MAOAMAOB
SCHEMBL4129565 0.83 DRD2 (0.53) DRD2SIGMAR1TDP1MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250032623-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. 2025-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250032623-A1 HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE AURKB, CDK9, AURKA DRD2 3690/4885SIGMAR1 4785/4885TDP1 1293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.